This site is intended for Healthcare Professionals only.

Paul Burden elected BGMA Vice-Chair, bringing 25 years of industry leadership


Share post:

Veteran of off-patent sector to drive strategic engagement and patient access initiatives at BGMA

The British Generic Manufacturers Association (BGMA) has announced the election of Paul Burden, currently the UK Vice President Rx for Stada Thornton & Ross, as its next vice-chair.

The appointment, effective immediately, underscores Burden’s 25 years of experience within the off-patent medicines sector.

Burden’s career spans various commercial leadership roles with prominent companies such as Arrow Generics, Mylan, Teva, and Advanz.

Since 2011, Burden has been involved with the BGMA, chairing the economic and commercial working group for four years.

His influence shaped the association’s stance on critical issues such as generic pricing, the falsified medicines directive, economic data, voluntary schemes, and supply chain challenges.

In accepting his new role, Burden expressed commitment to enhancing recognition of off-patent medicines’ role in NHS patient care:

“Off-patent medicines represent the vast majority of prescription products taken by NHS patients, so it is vitally important their contribution is properly recognised by clinicians and policymakers alike.”

He emphasised his dedication to ensuring the UK maintains a robust, competitive, and sustainable off-patent pharmaceutical sector.

Mark Samuels, Chief Executive of the BGMA, hailed Burden’s appointment, highlighting his extensive industry leadership:

“We are very fortunate to be able to call upon the experience of someone like Paul who has held so many senior positions in our sector. His input as vice-chair will be vital in the next phase of the association’s engagement.”

Burden will succeed Diane DiGangi-Trench as BGMA vice-chair when her tenure concludes, continuing the association’s mission to support the Department of Health & Social Care and the NHS in improving patient access to affordable medicines.

The BGMA represents major players in the UK generic medicines market, supplying approximately 85 per cent of the market by volume and contributing significantly to NHS cost savings.

With over a billion generic items prescribed annually, the association plays a crucial role in ensuring medication affordability and availability across the healthcare system.


Please enter your comment!
Please enter your name here


Related articles

Wes Streeting reaffirms mission to cut NHS waiting lists during Heatherwood Hospital visit

Streeting called the NHS "broken," with millions of patients facing long waits for treatment  Health and Social Care Secretary...

PDA now significantly involved in medicines related humanitarian projects

The PDA joined the International Pharmaceutical Federation (FIP) in 2022, gaining access to over 150 global pharmacy organizations...

Ultra-processed foods constitute nearly two-thirds of UK adolescents’ calorie intake, NIHR study finds

Consumption of ultra-processed foods found highest among adolescents from deprived backgrounds, those of white ethnicity and younger adolescents A...

PAGB urges Labour government to prioritise self-care in first 100 days for positive health impact

PAGB says self-care could save NHS £1.7bn by reducing 30 Million unnecessary GP and A&E visits annually and...